# Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis

> **NCT00515450** · PHASE3 · COMPLETED · sponsor: **Benesis Corporation** · enrollment: 46 (estimated)

## Conditions studied

- Generalized Myasthenia Gravis

## Interventions

- **BIOLOGICAL:** GB-0998 (Intravenous immunoglobulin)
- **PROCEDURE:** Plasmapheresis

## Key facts

- **NCT ID:** NCT00515450
- **Lead sponsor:** Benesis Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2010-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00515450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00515450, "Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00515450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*